Par Financial Statements From 2010 to 2025

Stocks . India . 
Stock . Par Drugs And
PAR Stock   98.62  3.81  4.02%   
Par Drugs financial statements provide useful quarterly and yearly information to potential Par Drugs And investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Par Drugs financial statements helps investors assess Par Drugs' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Par Drugs' valuation are summarized below:
Gross Profit
649.9 M
Profit Margin
0.152
Market Capitalization
1.2 B
Enterprise Value Revenue
0.9698
Revenue
1 B
There are over eighty available trending fundamental ratios for Par Drugs And, which can be analyzed over time and compared to other ratios. Investors should ensure to check out all of Par Drugs' recent performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road.

Par Drugs Total Revenue

669.2 Million

Check Par Drugs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Par Drugs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.2 M, Total Revenue of 669.2 M or Gross Profit of 736.4 M, as well as many indicators such as . Par financial statements analysis is a perfect complement when working with Par Drugs Valuation or Volatility modules.
  
This module can also supplement various Par Drugs Technical models . Check out the analysis of Par Drugs Correlation against competitors.

Par Drugs Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets763.9 M1.2 B692.8 M
Slightly volatile
Short and Long Term Debt Total139.5 M74.9 M190.5 M
Slightly volatile
Other Current Liabilities24.9 M24.2 M19.8 M
Slightly volatile
Total Current Liabilities123.4 M112 M170.2 M
Slightly volatile
Total Stockholder Equity1 B984.8 M427.9 M
Slightly volatile
Property Plant And Equipment Net305.2 M372 M390.1 M
Slightly volatile
Retained Earnings755.3 M719.3 M270 M
Slightly volatile
Accounts Payable75.1 M61.6 M67.1 M
Pretty Stable
Cash442.6 M421.5 M122.3 M
Slightly volatile
Non Current Assets Total311.6 M377.9 M397.9 M
Slightly volatile
Non Currrent Assets Other6.3 M5.8 M7.5 M
Slightly volatile
Cash And Short Term Investments442.6 M421.5 M122.3 M
Slightly volatile
Net Receivables140.6 M157.7 M113.6 M
Slightly volatile
Common Stock Shares Outstanding11.2 M14.2 M9 M
Slightly volatile
Liabilities And Stockholders Equity763.9 M1.2 B692.8 M
Slightly volatile
Non Current Liabilities Total30.3 M31.9 M118.7 M
Slightly volatile
Inventory34.4 M39.8 M47.5 M
Slightly volatile
Total Liabilities203.6 M143.8 M292 M
Slightly volatile
Total Current Assets720 M685.7 M305 M
Slightly volatile
Common Stock75.5 M141.5 M60.6 M
Slightly volatile
Current Deferred Revenue43.6 K45.9 K11 M
Pretty Stable
Other Liabilities41.5 M45.5 M36.7 M
Slightly volatile
Net Tangible Assets433.3 M688.6 M334.6 M
Slightly volatile
Net Invested Capital631.7 M984.8 M518.9 M
Slightly volatile
Non Current Liabilities Other1.3 K9002 K
Slightly volatile
Property Plant Equipment286.9 M309.2 M363 M
Slightly volatile
Short Term Investments1.1 K1.1 K3.8 M
Slightly volatile
Capital Stock98.4 M141.5 M71 M
Slightly volatile
Property Plant And Equipment Gross455.1 M372 M556 M
Slightly volatile

Par Drugs Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization33.2 M39.5 M29.8 M
Slightly volatile
Total Revenue669.2 M1.1 B556.7 M
Slightly volatile
Gross Profit736.4 M701.4 M284.6 M
Slightly volatile
Other Operating Expenses520 M465.5 M417.5 M
Slightly volatile
Operating Income666 M634.3 M172.4 M
Slightly volatile
EBIT235.7 M224.4 M99 M
Slightly volatile
EBITDA142.9 M264 M121 M
Slightly volatile
Cost Of Revenue413.1 M398.5 M302.1 M
Slightly volatile
Total Operating Expenses77.7 M52.5 M112.6 M
Slightly volatile
Income Before Tax235.7 M224.4 M80.7 M
Slightly volatile
Net Income175.1 M166.8 M58.7 M
Slightly volatile
Income Tax Expense60.6 M57.7 M22 M
Slightly volatile
Interest Expense915.7 K963.9 K14.3 M
Slightly volatile
Selling General Administrative11.4 M18.9 M8.8 M
Slightly volatile
Selling And Marketing Expenses65 M61.9 M23.9 M
Slightly volatile
Tax Provision29.1 M57.7 M21.6 M
Slightly volatile
Interest Income2.8 M2.7 M1 M
Slightly volatile
Net Income From Continuing Ops87 M166.8 M57 M
Slightly volatile
Research Development4 M3.8 M1 M
Slightly volatile
Reconciled Depreciation34.1 M39.5 M31.9 M
Slightly volatile
Net Income Applicable To Common Shares65.2 M106 M47.4 M
Slightly volatile

Par Drugs Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow171.1 M162.9 M79.6 M
Slightly volatile
Depreciation33.2 M39.5 M29.8 M
Slightly volatile
Dividends Paid18.6 M17.7 M6.1 M
Slightly volatile
Capital Expenditures73.4 M69.9 M26 M
Slightly volatile
Total Cash From Operating Activities244.5 M232.9 M105.6 M
Slightly volatile
Net Income88.5 M166.8 M62.6 M
Slightly volatile
End Period Cash Flow442.6 M421.5 M122.3 M
Slightly volatile
Begin Period Cash Flow268.6 M255.8 M78.8 M
Slightly volatile

Par Fundamental Market Drivers

Cash And Short Term Investments366.5 M

About Par Drugs Financial Statements

Par Drugs stakeholders use historical fundamental indicators, such as Par Drugs' revenue or net income, to determine how well the company is positioned to perform in the future. Although Par Drugs investors may analyze each financial statement separately, they are all interrelated. For example, changes in Par Drugs' assets and liabilities are reflected in the revenues and expenses on Par Drugs' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Par Drugs And. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue45.9 K43.6 K
Total Revenue1.1 B669.2 M
Cost Of Revenue398.5 M413.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Other Information on Investing in Par Stock

Par Drugs financial ratios help investors to determine whether Par Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Par with respect to the benefits of owning Par Drugs security.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Cash Flow
Statement
Details
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY